CD8A and neoplasm: To directly test whether the antitumor effect of CY12-RP2 depends on CD8+ T cells, given their redistribution across tumor, spleen, and lymph node compartments, targeted depletion of CD8+ T cells was implemented using anti-CD8α antibodies in B16-F10 tumor-bearing C57BL/6 mice.